KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Quest Diagnostics (DGX) EBT: 2009-2025

Historic EBT for Quest Diagnostics (DGX) over the last 17 years, with Sep 2025 value amounting to $328.0 million.

  • Quest Diagnostics' EBT rose 10.81% to $328.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 15.63%. This contributed to the annual value of $1.2 billion for FY2024, which is 3.98% up from last year.
  • According to the latest figures from Q3 2025, Quest Diagnostics' EBT is $328.0 million, which was down 14.58% from $384.0 million recorded in Q2 2025.
  • In the past 5 years, Quest Diagnostics' EBT registered a high of $817.0 million during Q2 2021, and its lowest value of $109.0 million during Q4 2022.
  • For the 3-year period, Quest Diagnostics' EBT averaged around $299.4 million, with its median value being $299.0 million (2024).
  • As far as peak fluctuations go, Quest Diagnostics' EBT soared by 430.51% in 2021, and later slumped by 78.29% in 2022.
  • Over the past 5 years, Quest Diagnostics' EBT (Quarterly) stood at $502.0 million in 2021, then plummeted by 78.29% to $109.0 million in 2022, then surged by 117.43% to $237.0 million in 2023, then grew by 26.16% to $299.0 million in 2024, then increased by 10.81% to $328.0 million in 2025.
  • Its EBT stands at $328.0 million for Q3 2025, versus $384.0 million for Q2 2025 and $276.0 million for Q1 2025.